Cerebral metastases of cutaneous melanoma

Br J Cancer. 1997;76(2):256-9. doi: 10.1038/bjc.1997.371.

Abstract

Cerebral metastases of cutaneous melanoma carry a very poor prognosis. We report our experience of 31 patients who presented with cerebral metastasis of cutaneous melanoma in a 5-year period between mid-1991 and mid-1996. Cerebral metastases were diagnosed on computerized tomography (CT) scan after patients became symptomatic. The overall median survival in our series was 4 months. Seventeen patients (55%) received treatment with radiotherapy and dexamethasone with resolution of their symptoms, although median survival remained at 4 months. Six patients (19%) had surgery followed by whole brain radiotherapy, with median survival of 5 months. The remaining eight patients received dexamethasone alone. Data from patients surviving less than 2 months and over 6 months suggest that the poor prognostic factors are the presence of more than one cerebral metastasis and additional extracranial metastases.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Brain Neoplasms / mortality
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy
  • Chemotherapy, Adjuvant
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Male
  • Melanoma / mortality
  • Melanoma / secondary*
  • Melanoma / therapy
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy
  • Survival Rate
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents, Hormonal
  • Dexamethasone